1. Home
  2. STBA vs HROW Comparison

STBA vs HROW Comparison

Compare STBA & HROW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo S&T Bancorp Inc.

STBA

S&T Bancorp Inc.

SELL

Current Price

$48.55

Market Cap

1.8B

Sector

Finance

ML Signal

SELL

HROW

Harrow Inc.

SELL

Current Price

$29.19

Market Cap

1.7B

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
STBA
HROW
Founded
1902
1998
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.8B
1.7B
IPO Year
1995
2008

Fundamental Metrics

Financial Performance
Metric
STBA
HROW
Price
$48.55
$29.19
Analyst Decision
Hold
Strong Buy
Analyst Count
7
9
Target Price
$53.33
★ $65.00
AVG Volume (30 Days)
260.6K
★ 601.4K
Earning Date
10-22-2026
11-09-2026
Dividend Yield
★ 3.08%
N/A
EPS Growth
2.35
★ 71.43
EPS
★ 1.96
N/A
Revenue
N/A
N/A
Revenue This Year
$3.87
$28.59
Revenue Next Year
$3.75
$53.17
P/E Ratio
$24.52
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$34.38
$27.00
52 Week High
$53.50
$54.98

Technical Indicators

Market Signals
Indicator
STBA
HROW
Relative Strength Index (RSI) 43.06 24.37
Support Level $47.65 $28.54
Resistance Level $48.70 $35.43
Average True Range (ATR) 0.85 1.27
MACD -0.07 -0.04
Stochastic Oscillator 40.52 29.20

Price Performance

Historical Comparison
STBA
HROW

About STBA S&T Bancorp Inc.

S&T Bancorp Inc is a financial holding company providing a full range of financial services to individuals and businesses in Pennsylvania and Ohio, including retail and commercial banking products, cash management, and trust and brokerage services. Through its subsidiary, it offers consumer, commercial, and small business banking services, including time and demand deposits, commercial and consumer loans, brokerage and trust services, and manages private investment accounts for individuals and institutions. The company earns revenue mainly from interest on loans and securities and fees for financial services, with net interest income as the principal source of revenue, and incurs expenses for deposits, funding sources, provision for credit losses, and operating costs.

About HROW Harrow Inc.

Harrow Inc is an eyecare pharmaceutical company engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the U.S. market. The company partners with U.S. eyecare professionals to develop products used to manage ophthalmic conditions affecting both the front and back of the eye, such as dry eye disease, cataracts, refractive errors, glaucoma, etc. Its portfolio of branded ophthalmic pharmaceuticals includes Iheezo, Vevye, Byooviz Opuviz, Natacyn, Maxitrol, Maxidex, etc. Additionally, the company's development pipeline comprises candidates like MELT-300, H-N08, CR-01, and MELT-210, being developed to address unmet needs in eye care and selected adjacent markets. Its reportable segments are: Branded, which derives maximum revenue, and ImprimisRx.

Share on Social Networks: